Home » Newsletters » BioWorld Science

BioWorld Science

May 16, 2018

View Archived Issues

Potential association of lonafarnib treatment with reduced mortality in children with HGPS

GAPVAC-101 trial of biomarker-guided actively personalized vaccines for glioblastoma completed

Phase II results presented for eculizumab in the treatment of Guillain-Barre syndrome

No improvement seen with LHA-510 in wet age-related macular degeneration trial

TapImmune and Marker Therapeutics agree to merger

PhoreMost receives new funding

Lilly gains AK-01 with AurKa Pharma acquisition

Shionogi patents new P2X7 antagonists

BioCryst Pharmaceuticals discloses kallikrein inhibitors

Tesaro identifies new CSF1R inhibitors

Roche discloses new TLR7 agonists for HBV infections

Medshine Discovery and collaborator present HGF receptor inhibitors

Novartis completes tender offer for outstanding shares of AveXis

Idorsia initiates registration study of lucerastat in adults with Fabry disease

Dimerix announces plans for phase II trials with DMX-200 in chronic kidney disease

CARB-X supports MicrobeDx's development of UTI diagnostic system

Aerie submits NDA to FDA for Roclatan

Inovio reports new data from phase I study of HIV vaccine Pennvax-GP

Otsuka highlights progress of first quarter 2018

FDA approves Truvada to reduce risk of HIV-1 infection in adolescents

V21-DOS47 immunoconjugate shows promising antitumoral activity in vivo

Pivotal study of Dupixent in moderate to severe atopic dermatitis in adolescents meets key endpoints

BioLamina and Novo Nordisk partner to develop novel stem cell-based therapies based on Biolaminins

Rexahn advances phase IIa study of RX-3117 and Abraxane in metastatic pancreatic cancer